AIM:BMK

Stock Analysis Report

Executive Summary

Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge for the development of food and farming industries worldwide.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.

Share Price & News

How has Benchmark Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.1%

BMK

-3.2%

GB Pharmaceuticals

0.2%

GB Market


1 Year Return

-13.9%

BMK

9.5%

GB Pharmaceuticals

1.7%

GB Market

Return vs Industry: BMK underperformed the UK Pharmaceuticals industry which returned 9.5% over the past year.

Return vs Market: BMK underperformed the UK Market which returned 1.7% over the past year.


Shareholder returns

BMKIndustryMarket
7 Day8.1%-3.2%0.2%
30 Day-3.1%-6.2%-1.7%
90 Day-11.4%3.5%-3.1%
1 Year-13.9%-13.9%12.9%9.5%6.7%1.7%
3 Year-28.5%-28.5%46.6%31.8%17.7%3.1%
5 Year-44.0%-44.0%83.7%52.2%36.1%5.5%

Price Volatility Vs. Market

How volatile is Benchmark Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Benchmark Holdings undervalued compared to its fair value and its price relative to the market?

0.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BMK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BMK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BMK is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: BMK is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BMK is good value based on its PB Ratio (0.7x) compared to the GB Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Benchmark Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

75.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: BMK is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: BMK's loss is forecast to worsen by 0% next year.

Revenue vs Market: BMK's revenue (14.8% per year) is forecast to grow faster than the UK market (3.9% per year).

High Growth Revenue: BMK's revenue (14.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BMK is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Benchmark Holdings performed over the past 5 years?

-11.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BMK is unprofitable, and losses have increased over the past 5 years at a rate of -11.2% per year.

Accelerating Growth: Unable to compare BMK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-12.4%).


Return on Equity

High ROE: BMK has a negative Return on Equity (-4.65%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BMK is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BMK is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Benchmark Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: BMK's short term assets (£100.1M) exceeds its short term liabilities (£42.2M)

Long Term Liabilities: BMK's short term assets (100.1M) do not cover its long term liabilities (127.4M)


Debt to Equity History and Analysis

Debt Level: BMK's debt to equity ratio (24.4%) is considered satisfactory

Reducing Debt: BMK's debt to equity ratio has increased from 0.5% to 24.4% over the past 5 years.


Balance Sheet

Inventory Level: BMK has a high level of physical assets or inventory.

Debt Coverage by Assets: BMK's debt is covered by short term assets (assets are 1.120550x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BMK has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.9% each year.


Next Steps

Dividend

What is Benchmark Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%2.0%markettop25%5.4%industryaverage3.1%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BMK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BMK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BMK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: BMK is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMK's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Benchmark Holdings's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Malcolm David Pye (62yo)

18.9yrs

Tenure

UK£554,452

Compensation

Mr. Malcolm David Foster Pye serves as the Chief Executive Officer at Benchmark Holdings plc since November 2000. He Founded Benchmark Holdings plc in 2000. Mr. Pye works within Benchmark Holdings companie ...


CEO Compensation Analysis

Compensation vs. Market: Malcolm David's total compensation ($USD719.62K) is about average for companies of similar size in the UK market ($USD884.56K).

Compensation vs Earnings: Malcolm David's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.4yrs

Average Tenure

58yo

Average Age

Experienced Management: BMK's management team is considered experienced (3.4 years average tenure).


Board Age and Tenure

1.9yrs

Average Tenure

57yo

Average Age

Experienced Board: BMK's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: BMK insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£87,00011 Oct 19
Alexander Raeber
EntityIndividual
Role
Member of the Board of Directors
Chief Scientific Officer & Executive Director
Shares200,000
Max PriceUK£0.43
BuyUK£470,00016 Sep 19
Peter George
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares1,000,000
Max PriceUK£0.47
BuyUK£134,28916 Sep 19
Yngve Myhre
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares300,000
Max PriceUK£0.47
BuyUK£57,50012 Dec 18
Yngve Myhre
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares100,000
Max PriceUK£0.57

Ownership Breakdown


Management Team

  • Athene Blakeman

    Company Secretary & Group Legal Counsel

    • Tenure: 5.1yrs
  • Peter George (58yo)

    Executive Chairman

    • Tenure: 1.4yrs
    • Compensation: UK£48.31k
  • Malcolm David Pye (62yo)

    CEO & Executive Director

    • Tenure: 18.9yrs
    • Compensation: UK£554.45k
  • Roland Bonney (55yo)

    Group Lead of Key Account Management

    • Tenure: 1.8yrs
    • Compensation: UK£271.00k
  • Mark Plampin (51yo)

    CFO & Executive Director

    • Tenure: 5.8yrs
    • Compensation: UK£445.72k
  • Ruth Layton

    Co-Founder & Head of Benchmark Sustainability Science

    • Tenure: 0yrs
    • Compensation: UK£14.18k
  • Anna Winton

    Head of People

    • Tenure: 0yrs
  • Ivonne Cantu

    Director of Investor Relations Director & Corporate Development

    • Tenure: 0yrs
  • Alex Raeber (58yo)

    Chief Scientific Officer & Executive Director

    • Tenure: 1yrs
  • Doerte Laue

    Marketing Director

    • Tenure: 1yrs

Board Members

  • Kevin Quinn (59yo)

    Non-Executive Director

    • Tenure: 2.9yrs
    • Compensation: UK£45.00k
  • Yngve Myhre (50yo)

    Non-Executive Director

    • Tenure: 1.9yrs
    • Compensation: UK£40.69k
  • Kristian Eikre (41yo)

    Non-Executive Director

    • Tenure: 0.6yrs
  • Susan Jane Searle (56yo)

    Senior Independent Director

    • Tenure: 0yrs
    • Compensation: UK£45.00k
  • Peter George (58yo)

    Executive Chairman

    • Tenure: 1.4yrs
    • Compensation: UK£48.31k
  • Malcolm David Pye (62yo)

    CEO & Executive Director

    • Tenure: 18.9yrs
    • Compensation: UK£554.45k
  • Mark Plampin (51yo)

    CFO & Executive Director

    • Tenure: 5.8yrs
    • Compensation: UK£445.72k
  • Hugo Wahnish

    Non-Executive Director

    • Tenure: 1.9yrs
    • Compensation: UK£40.69k
  • Alex Raeber (58yo)

    Chief Scientific Officer & Executive Director

    • Tenure: 1yrs

Company Information

Benchmark Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Benchmark Holdings plc
  • Ticker: BMK
  • Exchange: AIM
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£259.774m
  • Shares outstanding: 558.65m
  • Website: https://www.benchmarkplc.com

Number of Employees


Location

  • Benchmark Holdings plc
  • Benchmark House
  • 8 Smithy Wood Drive
  • Sheffield
  • South Yorkshire
  • S35 1QN
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMKAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2013
BHCC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDDec 2013
31BDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2013

Biography

Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge for the development of food and farming industries worldwide. The company operates th ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 21:22
End of Day Share Price2019/10/21 00:00
Earnings2019/03/31
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.